Palexia Retard (Tapentadol Hydrochloride)

Tapentadol hydrochloride, the active ingredient in Palexia Retard, is an opioid analgesic presented as a prolonged‑release oral tablet for systemic use. It is indicated for the management of moderate to severe chronic pain in adult patients when alternative treatments are inadequate. GNH USA supplies Palexia Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Palexia Retard is an opioid analgesic that acts on the central nervous system to relieve persistent pain conditions. - Chronic low back pain: provides long‑lasting relief of moderate to severe pain when other analgesics are insufficient. - Osteoarthritis pain: reduces pain intensity and improves functional ability in adults with severe joint degeneration. - Neuropathic pain associated with diabetic peripheral neuropathy: alleviates burning and shooting pain where first‑line agents are ineffective.

Tapentadol may cause a range of adverse reactions, from mild to potentially life‑threatening.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel movements. - Dizziness: sensation of light‑headedness. - Somnolence: increased sleepiness. - Headache: mild throbbing pain. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that may be fatal. - Seizures: convulsive episodes, especially at high doses. - Severe hypotension: marked drop in blood pressure. - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Dependence or abuse potential: risk of misuse with prolonged use. - Adrenal insufficiency: rare hormonal imbalance affecting stress response.

Before prescribing Palexia Retard, clinicians should evaluate patient history and monitor for specific safety concerns. - Assess renal function: dose adjustment may be required in severe impairment. - Assess hepatic function: caution in patients with liver disease. - Evaluate for respiratory disorders: avoid in uncontrolled asthma or COPD. - Review concomitant CNS depressants: increased risk of sedation and respiratory depression. - Monitor for signs of addiction: watch for misuse or craving behaviors. - Store at ambient temperature: keep below 25°C in the original container, protected from moisture and direct sunlight.

Tapentadol interacts with several drug classes; careful review of a patient’s medication list is essential.

Major Interactions (Avoid): - Benzodiazepines: additive central nervous system depression. - Barbiturates: heightened risk of respiratory depression. - Monoamine oxidase inhibitors (MAOIs): may precipitate hypertensive crisis. - CNS depressants (e.g., alcohol, opioids): synergistic sedation. - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increased tapentadol plasma levels.

Moderate Interactions (Monitor Closely): - Serotonergic agents (e.g., tramadol, SSRIs): risk of serotonin syndrome. - Antihistamines: enhanced drowsiness. - Antihypertensives: possible additive hypotensive effect. - Diuretics: may intensify orthostatic hypotension. - Anticonvulsants: potential alteration of seizure threshold.